Abstract
Bevacizumab plus platinum-doublet chemotherapy is effective as first-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC) in global populations. The efficacy benefit seen in mainly white patients is also consistently seen in Asian subpopulations. The BEYOND study was undertaken to confirm the efficacy and safety of first-line bevacizumab plus platinum-doublet chemotherapy in Chinese NSCLC patients.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call